Aligos Therapeutics Inc
ALGS10.680USD
+0.310+2.99%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
65.72MMarket Cap
LossP/E TTM
More Details of Aligos Therapeutics Inc Company
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Aligos Therapeutics Inc Info
Ticker SymbolALGS
Company nameAligos Therapeutics Inc
IPO dateOct 16, 2020
CEOBlatt (Lawrence M)
Number of employees70
Security typeOrdinary Share
Fiscal year-endOct 16
AddressOne Corporate Dr., 2Nd Floor
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone18004666059
Websitehttps://www.aligos.com/
Ticker SymbolALGS
IPO dateOct 16, 2020
CEOBlatt (Lawrence M)
Company Executives of Aligos Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Lawrence M. Blatt, Ph.D.
Dr. Lawrence M. Blatt, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
84.82K
-1.34%
Dr. Julian A. Symons
Dr. Julian A. Symons
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
15.76K
-0.01%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
3.61K
--
Dr. K. Peter Hirth, Ph.D.
Dr. K. Peter Hirth, Ph.D.
Independent Director
Independent Director
--
--
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Mr. Jordyn Tarazi
Mr. Jordyn Tarazi
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Ms. Margarita Chavez, J.D.
Ms. Margarita Chavez, J.D.
Independent Director
Independent Director
--
--
Dr. Hardean E. Achneck
Dr. Hardean E. Achneck
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Dr. Bridget A. Martell, M.D.
Dr. Bridget A. Martell, M.D.
Independent Director
Independent Director
--
--
Dr. Heather Preston, M.D.
Dr. Heather Preston, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Lawrence M. Blatt, Ph.D.
Dr. Lawrence M. Blatt, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
84.82K
-1.34%
Dr. Julian A. Symons
Dr. Julian A. Symons
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
15.76K
-0.01%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
3.61K
--
Dr. K. Peter Hirth, Ph.D.
Dr. K. Peter Hirth, Ph.D.
Independent Director
Independent Director
--
--
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Mr. Jordyn Tarazi
Mr. Jordyn Tarazi
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Woodline Partners LP
8.75%
Deep Track Capital LP
8.30%
Roche Holding AG
8.24%
Alyeska Investment Group, L.P.
7.70%
Sio Capital Management, LLC
6.28%
Other
60.75%
Shareholders
Shareholders
Proportion
Woodline Partners LP
8.75%
Deep Track Capital LP
8.30%
Roche Holding AG
8.24%
Alyeska Investment Group, L.P.
7.70%
Sio Capital Management, LLC
6.28%
Other
60.75%
Shareholder Types
Shareholders
Proportion
Hedge Fund
37.26%
Holding Company
8.24%
Investment Advisor/Hedge Fund
6.67%
Investment Advisor
5.39%
Individual Investor
2.13%
Research Firm
0.27%
Other
40.05%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
99
2.65M
78.55%
--
2025Q3
100
2.65M
78.58%
-54.48K
2025Q2
96
2.71M
78.40%
-591.18K
2025Q1
98
3.30M
44.66%
+927.05K
2024Q4
95
1.62M
61.88%
-71.59K
2024Q3
99
1.69M
71.32%
-199.58K
2024Q2
109
1.89M
69.76%
+43.14K
2024Q1
164
1.85M
77.15%
-391.07K
2023Q4
178
1.81M
51.28%
+784.62K
2023Q3
183
1.03M
93.36%
-22.19K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Woodline Partners LP
518.30K
9.69%
+202.92K
+64.34%
Jun 30, 2025
Deep Track Capital LP
444.11K
8.3%
--
--
Jun 30, 2025
Roche Holding AG
441.04K
8.24%
-1.00
-0.00%
Mar 06, 2025
Alyeska Investment Group, L.P.
412.00K
7.7%
--
--
Jun 30, 2025
Sio Capital Management, LLC
335.94K
6.28%
+155.22K
+85.89%
Jun 30, 2025
Readystate Asset Management LP
136.78K
2.56%
+91.38K
+201.28%
Jun 30, 2025
The Vanguard Group, Inc.
139.78K
2.61%
-973.00
-0.69%
Jun 30, 2025
Adage Capital Management, L.P.
140.00K
2.62%
-325.00K
-69.89%
Jun 30, 2025
Blatt (Lawrence M)
84.82K
1.59%
-1.15K
-1.34%
Mar 10, 2025
Baker Bros. Advisors LP
83.06K
1.55%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Schwab U.S. Small-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
Schwab U.S. Broad Market ETF
0%
Dimensional US Core Equity 1 ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Schwab U.S. Broad Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 15, 2024
Merger
25→1
Aug 15, 2024
Merger
25→1
Aug 15, 2024
Merger
25→1
Aug 15, 2024
Merger
25→1
Date
Type
Ratio
Aug 15, 2024
Merger
25→1
Aug 15, 2024
Merger
25→1
Aug 15, 2024
Merger
25→1
Aug 15, 2024
Merger
25→1
FAQs
Who are the top five shareholders of Aligos Therapeutics Inc?
The top five shareholders of Aligos Therapeutics Inc are:
Woodline Partners LP holds 518.30K shares, accounting for 9.69% of the total shares.
Deep Track Capital LP holds 444.11K shares, accounting for 8.30% of the total shares.
Roche Holding AG holds 441.04K shares, accounting for 8.24% of the total shares.
Alyeska Investment Group, L.P. holds 412.00K shares, accounting for 7.70% of the total shares.
Sio Capital Management, LLC holds 335.94K shares, accounting for 6.28% of the total shares.
Woodline Partners LP holds 518.30K shares, accounting for 9.69% of the total shares.
Deep Track Capital LP holds 444.11K shares, accounting for 8.30% of the total shares.
Roche Holding AG holds 441.04K shares, accounting for 8.24% of the total shares.
Alyeska Investment Group, L.P. holds 412.00K shares, accounting for 7.70% of the total shares.
Sio Capital Management, LLC holds 335.94K shares, accounting for 6.28% of the total shares.
What are the top three shareholder types of Aligos Therapeutics Inc?
The top three shareholder types of Aligos Therapeutics Inc are:
Woodline Partners LP
Deep Track Capital LP
Roche Holding AG
Woodline Partners LP
Deep Track Capital LP
Roche Holding AG
How many institutions hold shares of Aligos Therapeutics Inc (ALGS)?
As of 2025Q4, 99 institutions hold shares of Aligos Therapeutics Inc, with a combined market value of approximately 2.65M, accounting for 78.55% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.03%.
What is the biggest source of revenue for Aligos Therapeutics Inc?
In --, the -- business generated the highest revenue for Aligos Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
